New treatment strategies for hypertension: Which guidelines and how to apply them;Nouvelles stratégies thérapeutiques dans l'hypertension artérielle: Quelles recommandations et comment les appliquer?

Presse Medicale

Volumn 34, Issue 18, 2005, Pages 1279-1285

  Blacher, Jacques ^a   Baes, M ^b   Marchal, A ^b   Younes, W ^b   Legedz, L ^b   Safar, M ^b  

^a HÔTEL DIEU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIHYDRALAZINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; IMIDAZOLINE DERIVATIVE; MINERAL; MINOXIDIL; RESERPINE; STATINE DERIVATIVE; THIAZIDE DIURETIC AGENT; VITAMIN;

AORTA PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSULTATION; CORRELATION ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; EUROPE; HEALTH BEHAVIOR; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY DISEASE; KINESIOTHERAPY; ONSET AGE; PHYSICIAN; PRACTICE GUIDELINE; REVIEW; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; WHITE COAT HYPERTENSION; WORLD HEALTH ORGANIZATION;

EID: 27544498401     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84174-0     Document Type: Review

References (33)

1. Rapport sur la santé dans le monde. Réduire les risques et promouvoir une vie saine. Organisation Mondiale de la Santé, 2002.
2. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The Burden of Adult Hypertension in the United States 1999 to 2000: A Rising Tide. Hypertension 2004; 44: 398-404.
3. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1028-34.
4. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
5. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ 1998; 317: 167-71.
6. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39: 105-10.
7. Blacher J, Evans A, Arveiler D, Amouyel P, Ferrieres J, Bingham A et al. on behalf of the PRIME study group. Residual coronary risk in men aged 50-59 treated for hypertension and hyperlipidemia in the population. The PRIME study. J Hypertens 2004; 22: 415-23.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
9. Erratum in: JAMA 2003; 290: 197.
10. Gueyffier F, Boutitie F, Cornu C, Jullien G, Poncelet P, Sebaoun A et al. Presentation of OCTAVE II. A current epidemiologic study in France of the added prognostic value of ambulatory blood pressure monitoring. Arch Mal Cœur Vaiss 1996; 89: 1381-8.
11. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation 2000; 102: 1139-44.
12. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B et al. Cardiovascular prognosis of masked hypertension detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342-9.
13. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
14. Erratum in: J Hypertens 2003; 21: 2203-4.
15. J Hypertens 2004; 22: 435.
16. Safar ME, Smulyan H. Coronary ischemic disease, arterial stiffness, and pulse pressure. Am J Hypertens 2004; 17: 724-6.
17. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-9.
18. Pauca AL, Wallenhaupt SL, Kon ND, Tucker WY. Does radial artery pressure accurately reflect aortic pressure? Chest 1992; 102: 1193-8.
19. Mc Donald DA, Taylor MG. The hemodynamics of the arterial circulation. In: Progress in Biophysics, London: Pergamon Press 1959; 9: 107-73.
20. Safar M, Blacher J, Pannier B, Marchais S, Guyonvarc'h PM, London G. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-8.
21. Takazawa K, O'Rourke MF, Fujita M, Tanaka N, Takeda K, Kurosu F, Ibukiyama C. Estimation of ascending aortic pressure from radial arterial pressure using a generalized transfer function. Z Kardiol 1996; 85: 137-9.
22. Guidelines subcommittee. 1999 World Health Organization - Internal Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
23. Agence Nationale d'Accréditation et d'Evaluation en Santé. Prise en charge des patients adultes atteints d'HTA essentielle. Recommandations cliniques et données économiques. Paris: Anaes; avril 2000.
24. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998; 31: 823-9.
25. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-21.
26. Erratum in: N Engl J Med 1994; 330: 1689.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
28. Erratum in: JAMA 2003; 289: 178
29. JAMA 2004; 291: 2196.
30. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351: 1755-62.
31. Safar ME, Blacher J, Staessen JA. Hypertension Optimal Treatment (HOT) trial (correspondence). Lancet 1998; 352: 573.
32. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
33. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-70.